About Careers MedBlog Contact us

Long Term Solution for Organ Rejection Post Transplantation

by Anjali Aryamvally on December 9, 2017 at 11:59 AM
Font : A-A+

Long Term Solution for Organ Rejection Post Transplantation

Almost half of all organ recipients experience antibody-mediated organ rejection within ten years of the transplantation. Pharmacological agents for the suppression of chronic rejection are currently unavailable. While non-selective proteasome inhibitors can suppress antibody-mediated allograft rejection, their side effects severely limit their application.

Immunoproteasome inhibition, in contrast, has proved effective in preclinical models of autoimmune diseases and was applied over weeks without obvious adverse side effects. Using a rat model, the researchers, led by Marcus Groettrup, were able to show that immunoproteasome inhibition kills the activated plasma cells that produce allo-antibodies against the transplanted kidneys and lead to organ rejection. Selective immunoproteasome inhibition using the inhibitor ONX 0914 reduced the number of B cells and plasma cells and suppressed donor-specific allo-antibody production. The transplantations were performed by Dr Jun Li, a urological surgeon from the Cancer Institute Chongqing in China, who is an international expert for microsurgery and currently works at the University of Konstanz thanks to a scholarship awarded by the Chinese Scholarship Council.


"These results are a huge success. We can completely prevent organ rejection in all animals, also observing that allo-antibodies are virtually absent. The inflammation parameters in the transplanted kidneys decreased significantly and renal function in all recipients is excellent", summarises Marcus Groettrup, adding that these results suggest immunoproteasome inhibition as a promising therapeutic approach to suppress chronic antibody-mediated rejection.

Groettrup's structural model of the immunoproteasome is considered a milestone in the development of new agents in the fight against autoimmune diseases like diabetes, rheumatoid arthritis and multiple sclerosis. As early as the 2000s, Groettrup was able to define the immunoproteasome as a regulator of cytokines that are responsible for triggering autoimmune diseases. Pharmaceutical immunoproteasome inhibitors, which are presently tested in a first clinical trial, might allow us to fight autoimmune diseases and prevent the chronic rejection of transplant organs without compromising the patients' entire immune system.

Source: Eurekalert


Recommended Reading

Latest Organ Donation News

 COVID-19 Positive Donor Hearts Lower Survival in Transplant Patients
An analysis of data from donors suggests donor hearts from patients who were COVID-19 positive could place transplant patients at increased risk of mortality.
 Clinical Trial Suggests Paradigm Shift for Lung Transplantation
Patients subjected to delayed transplantation using 10°C static lung preservation had a better outcome compared to patients transplanted performed using standard methods.
New Method to Treat Chronic Transplant Rejection Discovered
Researchers are hoping to test the antibody IL-15 in organ transplant patients to reduce chronic organ rejection.
 Identifying Patients Who Need Liver Transplants Faster
Research may speed the identification of patients who need liver transplants by analyzing blood samples to look for biomarkers associated with liver failure.
How Can T Cells Help Prevent Marrow Transplant Complications?
The discovery of T cells involvement in graft-versus-host disease is a vital step in finding more effective life-saving treatments for bone marrow transplant.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Long Term Solution for Organ Rejection Post Transplantation Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests